Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

• ClinicalTrials.gov Identifier: NCT00658385
• Recruitment Status: Completed
• First Posted: April 15, 2008
• Results First Posted: November 25, 2016
• Last Update Posted: November 25, 2016
• Sponsor: Memorial Sloan Kettering Cancer Center
• Information provided by (Responsible Party): Memorial Sloan Kettering Cancer Center

Tracking Information

• First Submitted Date: April 10, 2008
• First Posted Date: April 15, 2008
• Results First Submitted Date: April 7, 2015
• Results First Posted Date: November 25, 2016
• Last Update Posted Date: November 25, 2016
• Study Start Date: April 2008
• Actual Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: October 4, 2016)

Number of Participants With no Serious Adverse Events [ Time Frame: Up to 14 Days ]

The entered value represents the number of participants with the absence of serious adverse events. G-CSF mobilization will be considered safe if there are no more than 1 of 5 patients with SAEs

• Original Primary Outcome Measures (submitted: April 10, 2008): To investigate the feasibility and safety of peripheral blood hematopoietic progenitor cell (HPC) mobilization with GCSF in patients with βthalassemia major and to determine the yield of CD34+ HPCs mobilized. [ Time Frame: conclusion of study ]
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures (submitted: April 10, 2008): To determine whether the collected HPCs are amenable to transduction with a lentiviral vector encoding the normal ßglobin gene. [ Time Frame: conclusion of study ]
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major
• Official Title: A Pilot Trial to Assess the Feasibility and Safety of GCSF Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major

Brief Summary

Betathalassemia major is a disease of the blood and bone marrow. You were born with it and it has made you unable to make normal hemoglobin and red cells. You have been receiving red blood cell transfusions all your life. These transfusions do not cure your disease. The problem with transfusions is that they contain a lot of iron. With time iron builds up in your body and will eventually hurt some of your organs . Because of this buildup of iron , you are taking medicine that helps your body get rid of the extra iron.

Today, the only other treatment is bone marrow or stem cell transplant. It can only be done when a matched donor is available. This is most often a brother, sister, or parent. Bone marrow transplant may cure betathalassemia major. If you have a transplant and it is successful, you will no longer have the disease. Without a matched sibling or parent, the standard treatment is to keep having transfusions.

In the near future, we will be testing a new treatment for making normal hemoglobin and normal red blood cells. We have recreated the healthy hemoglobin gene in a test tube. We are able to use it and put it back into cells. This is called gene therapy. We have been able to put this gene into the stem cells of mice with thalassemia. These mice were cured. We now plan to take that gene and put it into stem cells from people who have betathalassemia major. We will then inject those stem cells back into that person's blood.

In general, we can obtain more stem cells from the blood of a person than from the bone marrow . In order to do so, we must give that person a blood growth factor. The growth factor stimulates the bone marrow to make more stem cells. That growth factor is called granulocyte colony stimulating factor (GCSF), or Filgrastim.

The purpose of this trial is to find out if the drug GCSF has any side effects on you, and if you will make more stem cells in response to it. This trial is not a gene therapy trial. This trial will not help your thalassemia.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Beta Thalassemia Major
• Congenital Anemias

Intervention

Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)

Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.

These will be done again 24 hours after your stem cells are collected.

Study Arms

Experimental: 1

GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)

Intervention: Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: April 10, 2008): 5
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: February 2011
• Actual Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Subjects must be 18 years or older
• Subjects may be of either gender or of any ethnic background
• Subjects must have a confirmed diagnosis of ßthalassemia major and have been enrolled in a hypertransfusion program with a confirmed annual transfusion of ≥ or = to 100 mL/kg/yr AND ≥ or = to 8 Transfusions of blood per year over a minimum of two years.
• Patients must be off hydroxyurea (HU) or erythropoietin (EPO) treatment for at least three months prior to entry onto the study
• Subjects must have a performance score of Karnofsky > or = to 70 of the time of entry into the study.
• Subjects must have a normal EKG and a normal chest xray
• Each patient must be willing to participate as a research subject and must sign an informed consent form.
• Subjects must be splenectomized or have no palpable spleen
• Negative pregnancy test, if female

Exclusion Criteria:

• Active infections including Hepatitis B and C, HTLV 1 and 2, West Nile Virus, and HIV 1
• Female patient pregnant or breast feeding
• Patients with uncontrolled seizure disorders
• Allergy to GCSF or bacterial E. coli products
• History of sickle cell disease or sickle trait
• History of thrombosis or known thrombophilia

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00658385
• Other Study ID Numbers: 08-030
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Memorial Sloan Kettering Cancer Center
• Original Responsible Party: Farid Boulad, MD, Memorial Sloan-Kettering Cancer Center
• Current Study Sponsor: Memorial Sloan Kettering Cancer Center
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Farid Boulad, MD; Memorial Sloan Kettering Cancer Center

• PRS Account: Memorial Sloan Kettering Cancer Center
• Verification Date: October 2016